At the recent ESMO 2014 Congress in Madrid, Spain, researchers presented new data about mesothelioma treatment outcomes involving radiotherapy, also known as radiation therapy.
From this European Society for Medical Oncology (ESMO) report about some of the research results presented that conference, “Studies report new findings on treatment options for mesothelioma”:
“Mesothelioma remains a difficult disease to find better treatment options for, so we asked whether high-dose hemithoracic radiotherapy would decrease the rate or delay the time of local recurrence after chemotherapy and radical surgery,” says lead author Prof Rolf A. Stahel, from the Clinic and Policlinic for Oncology, at the University Hospital Zurich, Switzerland, and current President of the European Society for Medical Oncology….
While there had been preliminary evidence suggesting that the addition of radiotherapy might improve outcomes, the study failed to find any differences in relapse-free survival between patients treated with the additional radiotherapy, and those who were not.
Stahel says researchers were hoping for a more positive signal from the study. “We aimed for a six month delay in local recurrence, which would be meaningful because it’s an aggressive treatment for patients.”
In summary, Stahel says, “It demonstrates that, like in other solid tumours, when two modalities are not sufficient it’s very rare that the third modality
added would make a benefit.”
In our next post we will report on another malignant pleural mesothelioma study that was presented at the ESMO 2014 Congress.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.